Vertex, J&J to Begin New Telaprevir Study

In addition, one of the arms of the new study will see whether a "lead-in" treatment with interferon and ribavirin alone before dosing of telaprevir may improve overall cure rates.

Vertex and its partner are locked in a tight race with Schering-Plough(SGP Quote) to be the first with a new direct antiviral drug aimed at hepatitis C approved in the U.S. and Europe.

< Previous

1 2

Next >